CASE REPORT

Growth pattern and body proportion in a female with short stature homeobox-containing gene overdosage and gonadal estrogen deficiency

Tsutomu Ogata, Mikako Inokuchi and Masamichi Ogawa
Department of Pediatrics, Keio University School of Medicine, Tokyo and Ogawa Endocrine Clinic, Nagoya, Japan

(Received should be addressed to T Ogata, Department of Pediatrics, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan; Email: t-ogata@po.iijnet.or.jp)

Abstract

Objective: To report on growth pattern and body proportion in the combination of short stature homeobox-containing gene (SHOX) overdosage and gonadal estrogen deficiency.

Design: Auxological studies in a 20-year-old Japanese female with 45,X[28]/46.X.psidic(X)(q28)[72], gonadal estrogen deficiency, and SHOX duplication on the idic(X) chromosome, who received sex steroid replacement therapy from 16 years 8 months of age.

Methods: Growth pattern and body proportion were assessed by the age-matched standards for Japanese females.

Results: She continued to grow with a mean height velocity of 5.0 cm/year between 8 and 12 years of age and 4.4 cm/year between 12 and 16 years 8 months of age, and ceased to grow shortly after the replacement therapy. The standard deviation score (SDS) for height was 2.0.9, 2.1.4, 2.0.7 and 2.0.8 at 8, 12, 16 years 8 months and 20 years of age respectively. She showed a unique change in body proportion in her middle teens. At 8, 12, 16 years 8 months and 20 years of age, the SDS for sitting height (SH) was 2.0.8, 2.1.1, 2.0.9 and 2.0.6 respectively, the SDS for leg length (LL) was 2.0.8, 2.1.4, 2.1.1 and 2.1.4 respectively, and the SDS for SH/LL ratio was 2.1.6 and 2.1.7 respectively.

Conclusions: The results provide further support for the notion that the combination of SHOX overdosage and gonadal estrogen deficiency permits continued growth with a roughly constant height velocity throughout the pubertal period of normal children, and suggest that the height gain in that period is primarily ascribed to the LL increase, as expected from SHOX expression in the distal limb bones.

European Journal of Endocrinology 147 249–254

Introduction

SHOX (short stature homeobox-containing gene) is the first gene that has been shown to be relevant to the development of specific features in Turner syndrome. Clinical studies in patients with intragenic SHOX mutations and pseudoautosomal microdeletions involving SHOX as the sole disease gene have shown that SHOX haploinsufficiency causes not only short stature but also Turner skeletal features such as high arched palate, short neck, short metacarpals, cubitus valgus and Madelung deformity (1–4). Consistent with the distribution of skeletal lesions, SHOX is exclusively expressed in the first and second pharyngeal arches and in the developing distal limb bones of human embryos (3). Since SHOX haploinsufficiency results in compromised linear growth and unbalanced premature growth plate fusion of the distal limb bones (2,4,5), this implies that SHOX normally functions as a promoter for linear growth and as a repressor for growth plate fusion.

Growth failure and skeletal features in SHOX haploinsufficiency tend to be more severe in females than in males and to become obvious with puberty in individuals with normal gonadal function (2,4). Indeed, Leri–Weill dyschondrosteosis characterized by Madelung deformity and mesomelia is predominantly exhibited by pubertal or adult females. In this context, it has been suggested that gonadal estrogens exert a maturational effect on skeletal tissues that are susceptible to unbalanced premature growth plate fusion because of SHOX haploinsufficiency, facilitating growth deficiency and skeletal lesions in a female-dominant and pubertal tempo-influenced fashion (2). This notion postulates that SHOX haploinsufficiency and gonadal estrogens exert a synergic effect on
skeletal growth and maturation, and explains, in terms of serum estrogen concentration and the tempo of pubertal development, why skeletal lesions in SHOX haploinsufficiency are usually severe in early maturing females and are apparently absent or remain mild in males (2, 4).

Recently, it has been reported that the opposite combination of SHOX overdosage and gonadal estrogen deficiency leads to tall adult height because of continued growth with an almost constant height velocity from childhood through the pubertal period of normal children (6). This has been ascribed to the cooperation between SHOX overdosage and gonadal estrogen deficiency, which should exert a beneficial effect on linear growth and a marked suppressive effect on skeletal maturation. Since the growth pattern is similar to that in estrogen resistance or aromatase deficiency, which lacks biological effects of both gonadal and extragonadal estrogens (7), this suggests that an extra copy of SHOX has a potential to override the growth-suppressing and skeletal-maturing effect of extragonadal estrogens (6). Furthermore, tall stature with long legs has been reported in middle to late teenage females with der(X) chromosomes accompanied by distal Xp duplication and gonadal dysgenesis, suggesting that tall stature in the combination of SHOX overdosage and gonadal estrogen deficiency may primarily be ascribed to long legs (8–10).

However, clinical studies, especially longitudinal growth studies, remain poor for the combination of proven SHOX overdosage and gonadal estrogen deficiency, so that further studies are necessary to define the clinical features of the unique combination. In this paper, we report on longitudinal growth pattern and body proportion in a female with the association of SHOX overdosage with gonadal estrogen deficiency.

**Patient and methods**

**Patient**

This Japanese female was born at 40 weeks of gestation after an uncomplicated pregnancy and delivery. At birth, the length was 46.9 cm (−1.1 s.d.) and the weight 2.95 kg (−0.4 s.d.). The parents were non-consanguineous and clinically normal.

At 15 years 5 months of age, she presented with primary amenorrhea. Physical examination revealed no abnormality except for the lack of pubertal development. There were no discernible minor or major anomalies. The height was 154.7 cm (−0.3 s.d.) and the weight 56.9 kg (+0.6 s.d.). Basal serum follicle-stimulating hormone (FSH) was 47.6 IU/l (agematched normal range, 1.4–10.1 IU/l), luteinizing hormone 9.0 IU/l (0.2–15.1 IU/l), and estradiol below 30 pmol/l (45–620 pmol/l). She received conjugated estrogen (CE) (0.625 mg/day) from 16 years 8 months of age, and cyclic hormone replacement therapy consisting of CE on days 1–14, CE plus medroxyprogesterone acetate (5 mg/day) on days 15–21, and no drug on days 22–28 from 17 years 11 months of age. At present, she is 20 years old and shows sufficient pubertal development and regular menses.

**Methods**

**Conventional and molecular cytogenetic studies**

After obtaining informed consent, chromosome analysis was performed on peripheral lymphocytes by G-banding. Fluorescence in situ hybridization (FISH) analysis was performed for lymphocyte metaphase spreads, using probes for SHOX (2), DXZ1 (centromere) (Vysis, http://www.vysis.com/), the Xq telomere region (Vysis), and the whole X chromosome painting (WCPX) (Vysis). The SHOX probe was labeled with digoxigenin and detected by rhodamine anti-digoxigenin, and the remaining probes were detected according to the manufacturer’s protocol.

**Auxological studies**

Statural growth was evaluated by the longitudinal height and height velocity standards for Japanese females (11). Target height (TH) and target range (TR) were obtained from the equations of Ogata et al. (12) (a modified Tanner’s equation for the Japanese with a positive height secular trend). Sitting height (SH), leg length (LL, height minus SH), and SH/LL ratio were assessed by the age-matched standards for Japanese females (13). Pubertal stage was assessed by the classification of Tanner (14). Bone age was determined by the TW-2 method standardized for the Japanese (15).

**Results**

**Conventional and molecular cytogenetic studies**

Chromosome analysis showed a 45,X[28]/46,X,psu idic(X)(q28)[72] karyotype. FISH analysis revealed duplication of SHOX and DXZ1 on the idic(X) chromosome and deletion of the Xq telomere region from the idic(X) chromosome (Fig. 1). The WCPX probe homogeneously stained the entire idic(X) chromosome as well as the normal X chromosome.

**Auxological studies**

The data are summarized in Table 1 and Fig. 2. She had normal to low-normal height until her early teens, but continued to grow with a roughly constant height velocity until the initiation of CE replacement therapy. The mean height velocity was 5.0 cm/year between 8 and 12 years of age, and 4.4 cm/year between 12 and 16 years 8 months of age. She ceased to grow shortly after the CE replacement therapy with pubertal
and bone age progression, and had a final height of 161.9 cm (+0.8 S.D.), which was above her TH (159 cm, -0.3 S.D.) and within her TR (151–167 cm, -1.3±1.9 S.D.). The standard deviation score (SDS) for height gradually decreased from +0.9 at 8 years of age to -1.4 at 12 years of age and, then, steadily increased to +0.7 at 16 years 8 months of age and finally to +0.8 at 20 years of age.

She showed a dramatic change in body proportion in her middle teens. The SDS for SH remained almost constant from 8 until 20 years of age with the values of -0.8, -1.1, -0.9 and -0.6 at 8, 12, 16 years 8 months and 20 years of age respectively. By contrast, the SDS for LL, although it remained almost constant from 8 until 12 years of age with the values of -1.2 at 8 years of age and -1.4 at 12 years of age, steadily

---

**Table 1** Height, sitting height (SH), leg length (LL) and SH/LL ratio of this female.

<table>
<thead>
<tr>
<th>Age (years:months)</th>
<th>0:0</th>
<th>1:7</th>
<th>8:0</th>
<th>9:0</th>
<th>10:0</th>
<th>11:0</th>
<th>12:0</th>
<th>13:10</th>
<th>15:5</th>
<th>16:8</th>
<th>18:0</th>
<th>20:0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Height (cm)</td>
<td>46.9</td>
<td>77.0</td>
<td>119.9</td>
<td>125.7</td>
<td>130.0</td>
<td>135.5</td>
<td>139.9</td>
<td>150.3</td>
<td>154.7</td>
<td>160.3</td>
<td>161.6</td>
<td>161.9</td>
</tr>
<tr>
<td>(SDS)</td>
<td>-1.1</td>
<td>-1.2</td>
<td>-0.9</td>
<td>-0.8</td>
<td>-0.9</td>
<td>-1.1</td>
<td>-1.4</td>
<td>-1.0</td>
<td>-0.3</td>
<td>+0.7</td>
<td>+0.8</td>
<td>+0.8</td>
</tr>
<tr>
<td>SH (cm)</td>
<td>---</td>
<td>---</td>
<td>66.7</td>
<td>68.7</td>
<td>71.3</td>
<td>73.5</td>
<td>76.0</td>
<td>81.3</td>
<td>82.0</td>
<td>83.0</td>
<td>84.3</td>
<td>84.3</td>
</tr>
<tr>
<td>(SDS)</td>
<td>---</td>
<td>---</td>
<td>-0.8</td>
<td>-0.8</td>
<td>-0.6</td>
<td>-0.6</td>
<td>-1.0</td>
<td>-1.0</td>
<td>-0.9</td>
<td>-0.9</td>
<td>-0.6</td>
<td>-0.6</td>
</tr>
<tr>
<td>LL (cm)</td>
<td>---</td>
<td>---</td>
<td>53.2</td>
<td>57.0</td>
<td>58.7</td>
<td>62.0</td>
<td>63.9</td>
<td>69.0</td>
<td>72.7</td>
<td>77.0</td>
<td>77.3</td>
<td>77.5</td>
</tr>
<tr>
<td>(SDS)</td>
<td>---</td>
<td>---</td>
<td>-1.2</td>
<td>-1.1</td>
<td>-1.5</td>
<td>-1.1</td>
<td>-1.4</td>
<td>-0.8</td>
<td>+0.1</td>
<td>+1.1</td>
<td>+1.4</td>
<td>+1.4</td>
</tr>
<tr>
<td>SH/LL ratio</td>
<td>---</td>
<td>---</td>
<td>1.25</td>
<td>1.21</td>
<td>1.21</td>
<td>1.19</td>
<td>1.19</td>
<td>1.18</td>
<td>1.13</td>
<td>1.08</td>
<td>1.09</td>
<td>1.09</td>
</tr>
<tr>
<td>(SDS)</td>
<td>---</td>
<td>---</td>
<td>+0.6</td>
<td>+0.3</td>
<td>+0.9</td>
<td>+0.8</td>
<td>+0.4</td>
<td>+0.2</td>
<td>-0.9</td>
<td>-1.6</td>
<td>-1.7</td>
<td>-1.7</td>
</tr>
</tbody>
</table>

---
increased thereafter to +1.1 at 16 years 8 months of age and finally to +1.4 at 20 years of age. Consequently, the SDS for SH/LL ratio remained almost constant from 8 until 12 years of age with the values of +0.6 at 8 years of age and +0.4 at 12 years of age and, then, steadily decreased to −1.6 at 16 years 8 months of age and finally to −1.7 at 20 years of age.

**Discussion**

This female had a large isodicentric X chromosome with the breakpoint at Xq28. Consistent with the X chromosome rearrangement, endocrine studies showed FSH-dominant hypergonadotropic hypogonadism, which has been reported in Turner syndrome with gonadal dysgenesis (16), and FISH analysis revealed SHOX duplication on the idic(X) chromosome. Thus, this female represents a further case with the combination of SHOX overdosage and gonadal estrogen deficiency.

She exhibited a characteristic growth pattern. She continued to grow with a roughly constant height velocity from childhood through the middle teens in association with the upward shift of the height SDS until the initiation of CE. The growth pattern in her middle teens is noteworthy, because it is similar to that of the previously reported 29-year-old Japanese female with tall stature (172 cm, +2.9 s.d.) and 45,X[40]/46,X,der(X)[60] accompanied by SHOX duplication on the der(X) chromosome and gonadal dysgenesis untreated until 19 years of age (6). In this regard, it has been suggested that the growth pattern and tall stature of the previously reported female are inexplicable by SHOX duplication or gonadal estrogen deficiency alone but is explainable by assuming a synergic effect of the two factors (6). Thus, the growth pattern of this female would also be accounted for by the synergic effect of SHOX overdosage and gonadal estrogen deficiency.

The body proportion showed a unique change with age. The SDS for SH remained almost constant, but the SDS for LL steadily increased and the SDS for the SH/LL ratio steadily decreased in the middle teens. This implies that the height gain in her middle teens is primarily ascribed to the LL increase. Since SHOX is expressed in the distal limb region (3), and pure gonadal dysgenesis is usually associated with eunuchoid habitus with relatively long limbs (17, 18), it is inferred that SHOX overdosage and gonadal estrogen deficiency have primarily exerted a synergic effect on the limb bones, leading to the marked increase in the LL and
resultant change in the body proportion. This idea would explain why relatively tall stature in Klinefelter patients is almost totally ascribed to increased LL (19, 20), because Klinefelter patients have three copies of SHOX and hypogonadism.

For the growth pattern and body proportion of this female, the mosaicism with a 45,X cell lineage should be considered. In this regard, Turner females have severe growth failure and short LL in both childhood and adulthood (21, 22), and the height SDS of this female remained normal but below her TH SDS with a relatively short LL until her early teens and surpassed her TH SDS with a relatively long LL in her late teens. This would imply that the major growth determinant changed from the 45,X cell lineage to the 46,X, dic(X)(q28) cell lineage in her middle teens. Although the underlying mechanism for the switch of the dominant growth-controlling cell lineages remains to be clarified, it appears that, in a mosaic individual with gonadal estrogen deficiency, the growth-promoting effect of SHOX overdosage can override the growth-suppressing effect of SHOX haploinsufficiency in the pubertal period of normal children when the human growth is primarily subject to gonadal estrogens. In addition, since the 45,X cell lineage is ascribed to mitotic instability of the idic(X) chromosome, it would be less frequent in slowly dividing osteogenic cells than in rapidly dividing lymphocytes utilized for the karyotyping (23). This would also contribute to the growth promotion in her middle teens, as well as the growth preservation within the normal range in childhood. Consistent with the above notion, the previously described Japanese female with 45,X[40]/46,X,dic(X)(q28) also had low-normal height until her early teens and had tall stature in her late teens (6). and relatively tall stature (173 cm, +1.8 S.D.) with eunuchoid habitus has been reported in a 23-year-old female with primary amenorrhea and 45,X/46,X,idic(X)(q27) in whom a 45,X karyotype has been detected in 80% of lymphocytes (24).

In summary, the present study suggests that the combination of SHOX overdosage and gonadal estrogen deficiency leads to a roughly constant height velocity throughout the pubertal period of normal children primarily because of the LL increase, thereby showing a sharp contrast to the worsening of growth deficiency and mesomelic appearance with puberty in females with SHOX haploinsufficiency and normal ovarian function. Further studies in patients with this combination, especially in non-mosaic patients untreated until their late teens, will permit a better assessment of clinical features of this combination.

Acknowledgements

This work was supported in part by a grant for Pediatric Research from the Ministry of Health and Welfare, by Pharmacia Fund for Growth and Development Research, by a grant from Foundation for Growth Science, and by a grant from Human Science Foundation.

References


Received 28 December 2001
Accepted 7 May 2002